Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,442 Million (Small Cap)
NA (Loss Making)
NA
1.46%
-0.65
-0.18%
0.91
Revenue and Profits:
Net Sales:
785 Million
(Quarterly Results - Jun 2025)
Net Profit:
25 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
4.67%
0%
4.67%
6 Months
7.71%
0%
7.71%
1 Year
3.93%
0%
3.93%
2 Years
-13.45%
0%
-13.45%
3 Years
-21.02%
0%
-21.02%
4 Years
8.5%
0%
8.5%
5 Years
9.14%
0%
9.14%
Jinling Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
7.13%
EBIT Growth (5y)
-196.32%
EBIT to Interest (avg)
72.37
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.35
Sales to Capital Employed (avg)
0.84
Tax Ratio
100.00%
Dividend Payout Ratio
146.63%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.77%
ROE (avg)
3.84%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.91
EV to EBIT
-9.20
EV to EBITDA
13.19
EV to Capital Employed
0.75
EV to Sales
0.30
PEG Ratio
NA
Dividend Yield
1.46%
ROCE (Latest)
-8.15%
ROE (Latest)
-0.18%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Bullish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
785.50
805.50
-2.48%
Operating Profit (PBDIT) excl Other Income
54.60
59.00
-7.46%
Interest
1.70
0.90
88.89%
Exceptional Items
13.10
-1.10
1,290.91%
Consolidate Net Profit
25.20
25.20
Operating Profit Margin (Excl OI)
15.70%
20.80%
-0.51%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -2.48% vs -23.66% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 0.00% vs 146.49% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
3,260.50
2,767.10
17.83%
Operating Profit (PBDIT) excl Other Income
197.80
202.90
-2.51%
Interest
3.10
1.40
121.43%
Exceptional Items
-77.00
-0.90
-8,455.56%
Consolidate Net Profit
18.00
107.20
-83.21%
Operating Profit Margin (Excl OI)
8.80%
23.30%
-1.45%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 17.83% vs 4.36% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -83.21% vs -5.88% in Dec 2023
About Jinling Pharmaceutical Co., Ltd. 
Jinling Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






